What's new

Human medicines European public assessment report (EPAR): Imjudo, tremelimumab, Date of authorisation: 20/02/2023, Revision: 8, Status: Authorised

Human medicines European public assessment report (EPAR): Imjudo, tremelimumab, Date of authorisation: 20/02/2023, Revision: 8, Status: Authorised

Feb 18, 2025 - 16:18
 0
Human medicines European public assessment report (EPAR): Imjudo, tremelimumab, Date of authorisation: 20/02/2023, Revision: 8, Status: Authorised
Human medicines European public assessment report (EPAR): Imjudo, tremelimumab, Date of authorisation: 20/02/2023, Revision: 8, Status: Authorised
Read More

Tags:

Previous Article

STAT+: FDA’s head of device safety among employees terminated in ‘challenging’ w...

Next Article

Alabama hospital to adopt outpatient-only model through health system partnership

Related Posts

Drug-Eluting stent (DES) - Notified Body 2265 - 10/01/2...

Mar 13, 2025  0

Conduct of efficacy studies for intramammary products for use in cattle - Scientific guideline

Conduct of efficacy studies for intramammary products f...

Feb 21, 2025  0

Human medicines European public assessment report (EPAR): Vimkunya, Chikungunya vaccine (recombinant, adsorbed), Date of authorisation: 28/02/2025, Status: Authorised

Human medicines European public assessment report (EPAR...

Mar 24, 2025  0